10 stocks everyone's whispering about

Leadership reshuffles, FDA approvals, dividend bombs, and job cuts—India's most talked-about stocks are buzzing for all the right (and wrong) reasons. From TCS's hush-hush increment freeze to Paytm's regulatory déjà vu, here's the latest heat check on the headlines. Suppose you eavesdrop on the stock market this week. In that case, you'll hear some unusually juicy gossip—TCS is holding back pay hikes (but generously doling out dividends), Biocon's breaking into new pharma territory overseas, and Sun Pharma just dodged a legal landmine to launch a new drug. Meanwhile, BHEL wandered into fertiliser factories, HDFC Bank remains everyone's favourite poster child, and Asian Paints might be brushing up for a rebound. Tata Steel is trimming jobs in Europe, Adani is plotting spin-offs, Coal India is making your savings account jealous with its dividend yield, and Paytm... well, Paytm's back in trouble (again). It's a week where the balance sheets are as lively as the boardrooms, and this roundup gives you the full download—with all the sizzle, speculation, and stock ratings you need. TCS (Tata Consultancy Services) Price (INR): Rs 3,231.50 (April 11, 2025) 52-Week Range (INR): Rs 3,056.05 - Rs 4,592.25 Value Research Rating: ★★★★ (4-star) Quality - 10/10 Growth - 6/10 Valuation - 5/10 Momentum - 1/10 TCS announced the appointment of Aarthi Subramanian as Executive Director and COO, effective May 2025. In parallel, the company deferred April salary hikes due to global economic uncertainty but will honour variable pay and plans to hire a